BridgeBio Pharma マネジメント

マネジメント基準チェック /24

BridgeBio Pharmaの CEO はNeil Kumarで、 Apr2015年に任命され、の在任期間は 9.67年です。の年間総報酬は$ 12.16Mで、 6.1%給与と93.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.65%を直接所有しており、その価値は€ 189.30M 。経営陣と取締役会の平均在任期間はそれぞれ5.5年と4.9年です。

主要情報

Neil Kumar

最高経営責任者

US$12.2m

報酬総額

CEO給与比率	6.1%
CEO在任期間	9.7yrs
CEOの所有権	3.7%
経営陣の平均在職期間	5.5yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Recent updates

CEO報酬分析

BridgeBio Pharma の収益と比較して、Neil Kumar の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$439m
Jun 30 2024	n/a	n/a	-US$454m
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

報酬と市場: Neilの総報酬 ($USD 12.16M ) は、 German市場 ($USD 3.33M ) の同規模の企業の平均を上回っています。

報酬と収益: Neilの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Neil Kumar (45 yo)

9.7yrs

在職期間

US$12,158,626

報酬

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Neil Kumar	Co-Founder	9.7yrs	US$12.16m	3.65% € 189.3m
Charles Homcy	Co-Founder	no data	US$1.11m	0.65% € 33.7m
Frank McCormick	Co-Founder	no data	US$1.74m	0.58% € 30.2m
Brian Stephenson	CFO & Secretary	6.2yrs	US$6.65m	0.050% € 2.6m
Richard Scheller	Chairman of Research & Development	5.9yrs	US$2.01m	データなし
Thomas Trimarchi	President & COO	less than a year	データなし	0.23% € 11.7m
Uma Sinha	Chief Scientific Officer	8.7yrs	US$2.75m	データなし
Grace Rauh	Vice President of Communications	no data	データなし	データなし
Eli Wallace	Chief Scientific Officer of Oncology	5yrs	データなし	データなし
Eric David	Chief Executive Officer of Gene Therapy	no data	データなし	データなし
Matthew Outten	Chief Commercial Officer	3.6yrs	データなし	データなし
Adora Ndu	Chief Regulatory Affairs Officer	2.9yrs	データなし	データなし

5.5yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: 2CLの経営陣は経験豊富で経験豊富です（平均在職期間は5.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Neil Kumar	Co-Founder	9.7yrs	US$12.16m	3.65% € 189.3m
Charles Homcy	Co-Founder	6.1yrs	US$1.11m	0.65% € 33.7m
Frank McCormick	Co-Founder	1.2yrs	US$1.74m	0.58% € 30.2m
Fred Hassan	Independent Director	3.3yrs	US$600.00k	0.010% € 528.9k
Ronald Daniels	Independent Director	4.8yrs	US$600.00k	0.0055% € 284.9k
Eric Aguiar	Independent Director	5.8yrs	US$600.00k	0% € 0
Randal Scott	Independent Director	4.5yrs	US$600.00k	0.0048% € 246.6k
Ali Satvat	Independent Director	8.8yrs	US$600.00k	0% € 0
James Momtazee	Director	8.8yrs	US$600.00k	0.047% € 2.4m
Jennifer Cook	Director	5yrs	US$600.00k	0.0038% € 195.8k
Wen-Chaun Lo	Independent Director	4.5yrs	US$600.00k	0.13% € 7.0m
Andrea Ellis	Independent Director	3.3yrs	US$600.00k	0.0063% € 329.0k

4.9yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: 2CLの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/26 06:14
終値	2024/12/23 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

BridgeBio Pharma, Inc. 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。24

アナリスト	機関
George Farmer	BMO Capital Markets Equity Research
Konstantinos Biliouris	BMO Capital Markets Equity Research
Jason Zemansky	BofA Global Research

BridgeBio Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

Insider recently bought €75k worth of stock

Independent Director recently bought €264k worth of stock

BridgeBio Pharma, Inc. Announces Executive Changes

Recent updates

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Approves Attruby™ (Acoramidis) for the Treatment of Adults with ATTR-CM

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Third quarter 2024 earnings released: US$0.86 loss per share (vs US$1.08 loss in 3Q 2023)

BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023)

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.92 loss in 1Q 2023)

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022)

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 21% undervalued

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Third quarter 2023 earnings released: US$1.08 loss per share (vs US$0.93 loss in 3Q 2022)

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022)

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.35 loss in 1Q 2022)

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

Third quarter 2022 earnings released: US$0.93 loss per share (vs US$1.06 loss in 3Q 2021)

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

Second quarter 2022 earnings released: US$0.067 loss per share (vs US$0.66 loss in 2Q 2021)

BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Insider recently bought €75k worth of stock

Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO).

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Independent Director recently bought €264k worth of stock

BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study

LianBio and BridgeBio Pharma, Inc. Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

Bridgebio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to Its Board of Directors

BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

QED Therapeutics and Partner Helsinn Group Announce FDA Approval of Truseltiq™ (infigratinib) for Patients with Cholangiocarcinoma

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

Forecast to breakeven in 2025

マネジメント基準チェック /24